$IONS News

Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $95

HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $115

Ionis Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

Ionis Pharmaceuticals, Inc. (IONS) Q2 2026 Earnings Call Transcript

Ionis Pharmaceuticals (NASDAQ:IONS) Surges After Q2 Earnings Beat Estimates

Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $895.148M Est

Ionis Pharmaceuticals Q2 Adj. EPS $(0.42) Beats $(1.07) Estimate, Sales $268.000M Beat $190.670M Estimate

Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $89

Ionis Pharmaceuticals: The Heartbreak Is Priced In

Wolfe Research Downgrades Ionis Pharmaceuticals to Peer Perform

RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $85

Ionis Pharmaceuticals Doses First Participant In Phase 1-2 ASCEND Study Of Ion337 For Dravet Syndrome, A Neurological Disorder

HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $125

Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $110

Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $90

Canaccord Genuity Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $95

Citigroup Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $100

Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $893.928M Est

Jefferies Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $90

Needham Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $86